Recent Updates
Recently added Catalysts
BMRN Positive Sentiment Score: 75/100

BioMarin to Present at 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 10:30 am PT /1:30 pm ET, in San Francisco, CA BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the...

Key Takeaway: BioMarin Pharmaceutical Inc. will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023. CEO Jean-Jacques Bienaimé will lead the presentation, which emphasizes the company's dedication to transforming lives through genetic discovery. BioMarin has established itself with eight successful therapies for rare genetic conditions and continues to pursue opportunities for first-to-market products in this area.

Market Sentiment Analysis

POSITIVE FACTORS

  • Jean-Jacques Bienaimé's presentation at a prestigious healthcare conference highlights BioMarin's industry presence.
  • The company has a strong history of innovative therapies addressing rare genetic disorders.
  • BioMarin's commitment to genetic discovery and targeted therapies positions it well for future growth.

Full Press Release Details

SAN RAFAEL, Calif. , Jan. 4, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 , at 10:30 am PT / 1:30 pm ET , in San Francisco, California . To access the live webcast, please visit the investor section of the BioMarin website, www.biomarin.com . A replay will also be archived on the site for at least one week following the event.
Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com .
Contacts: Investors/Media Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558
SOURCE BioMarin Pharmaceutical Inc.

21 %

Frequently Asked Questions

When will BioMarin present at the J.P. Morgan Healthcare Conference?

BioMarin will present on January 9, 2023, at 10:30 am PT.

Where can I watch the BioMarin conference presentation?

The live webcast is accessible on the investor section of BioMarin's website.

What is BioMarin's focus in biotechnology?

BioMarin focuses on developing therapies for genetic conditions.

How long will the conference replay be available?

A replay of the conference will be available for at least one week.

When was BioMarin Pharmaceutical founded?

BioMarin was founded in 1997.

Last updated: Jan 4, 2023